Malignant Endometrial Neoplasm
Associated Genetic Biomarkers
NCI Definition: Primary or metastatic malignant neoplasm involving the endometrium (mucous membrane that lines the endometrial cavity). 
Malignant endometrial neoplasms most frequently harbor alterations in PTEN, PIK3CA, TP53, ARID1A, and PIK3R1 .
PTEN Mutation, PIK3CA Mutation, TP53 Mutation, TP53 Missense, and TP53 c.217-c.1178 Missense are the most common alterations in malignant endometrial neoplasm .
There are 2 clinical trials for malignant endometrial neoplasm, of which 2 are open and 0 are completed or closed. Of the trials that contain malignant endometrial neoplasm as an inclusion criterion, 2 are phase 1 (2 open).
ERBB2, HER2, and TREM1 are the most frequent gene inclusion criteria for malignant endometrial neoplasm clinical trials .
Py159, paclitaxel, and pembrolizumab are the most common interventions in malignant endometrial neoplasm clinical trials.
Significant Genes in Malignant Endometrial Neoplasm
ERBB2 is altered in 8.72% of malignant endometrial neoplasm patients .
ERBB2 is an inclusion eligibility criterion in 2 clinical trials for malignant endometrial neoplasm, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and malignant endometrial neoplasm as inclusion criteria, 2 are phase 1 (2 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.